All In Biotech

Drug Trial Radar · NCT06380660

Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors

A Phase I/II, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of ACE-86225106 as Monotherapy in Patients With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

298

Planned (sponsor's estimate)

Start

Mar 22, 2024

Primary completion

Dec 21, 2028

Study completion Mar 21, 2029

Sponsor

Sponsor type
Industry
First posted
Apr 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if the experimental treatment with poly-ADP ribose polymerase (PARP) inhibitor, ACE-86225106 is safe, tolerable and has anti-cancer activity in adult patients with advanced solid tumors.

Conditions

  • Solid Tumor, Adult
  • BRCA1 Mutation
  • BRCA2 Mutation
  • Ovarian Cancer
  • Breast Cancer
  • Prostate Cancer

Interventions

  • ACE-86225106 tabletDrug

    ACE-86225106 will be administered orally daily as a continuous regimen. Subjects will continue to receive study treatment until PD as judged by local investigator review, development of unacceptable toxicity, or withdrawal of consent.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants experiencing adverse events (AEs)/serious adverse events (SAEs)Time frame: From time of information consent to 30 days post last dose, up to 3 years
  2. The number of patients experiencing dose limiting toxicity (DLT), as defined in the protocolTime frame: From the first dose of ACE-86225106 on Cycle 1 Day 1 up to and including the planned end of Cycle 1 (at the end of 28 days)
  3. Recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD)Time frame: Up to 3 years

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Chongqing Cancer Hospital

    Chongqing, Chongqing Municipality, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • Sun Yat-Sen University Cancer Center

    Guangzhou, Guangdong, China

  • Anyang Cancer Hospital

    Anyang, Henan, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Jinan Central Hospital

    Jinan, Shandong, China

  • Qilu Hospital Shangdong University

    Jinan, Shandong, China

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

  • Second Hospital Affiliated to Shanxi Medical University

    Taiyuan, Shanxi, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

  • First Hospital Affiliated to Wenzhou Medical University

    Wenzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.